FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Oliver Hanemann

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Procedures

Immunohistochemistry

Physiology

Genes & Molecular Sequences

Genes, Neurofibromatosis 2

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Alexander Schulz; Joachim Weis; Ansgar Zoch; Michiko Niwa-Kawakita; David B Parkinson; Stephan Schacke; J Michael Schröder; Stephan L Baader; Reinhard Bauer; Xin-Peng Dun; Cynthia Garcia; Marco Giovannini; David H Gutmann; Christian Hagel; C Oliver Hanemann; Marie Juliane Jung; Victor-Felix Mautner; Helen Morrison
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.
Scott R Plotkin; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat Stemmer-Rachamimov; Jeremie Vitte; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine MESSIAEN; Laura Papi; Jaishri Blakeley; D Gareth Evans; Marco Giovannini
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
Aditya Shivane; David B Parkinson; Sylwia Ammoun; C Oliver Hanemann
Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Oliver Hanemann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alexander Schulz; Joachim Weis; Ansgar Zoch; Michiko Niwa-Kawakita; David B Parkinson; Stephan Schacke; J Michael Schröder; Stephan L Baader; Reinhard Bauer; Xin-Peng Dun; Cynthia Garcia; Marco Giovannini; David H Gutmann; Christian Hagel; C Oliver Hanemann; Marie Juliane Jung; Victor-Felix Mautner; Helen Morrison
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.
Nature neuroscience 2013;16(4):426-33.
2013: Scott R Plotkin; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat Stemmer-Rachamimov; Jeremie Vitte; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine MESSIAEN; Laura Papi; Jaishri Blakeley; D Gareth Evans; Marco Giovannini
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
American journal of medical genetics. Part A 2013;161(3):405-16.
2013: Aditya Shivane; David B Parkinson; Sylwia Ammoun; C Oliver Hanemann
Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas.
Histopathology 2013;62(4):651-6.
2013: Robin D S Doddrell; Xin-Peng Dun; M Laura Feltri; C Oliver Hanemann; Aditya Shivane; Elisabeth Sock; Michael Wegner; Lawrence Wrabetz; David B Parkinson
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.
Brain : a journal of neurology 2013;136(Pt 2):549-63.
2012: Sylwia Ammoun; Camille Carroll; Emanuela Ercolano; David Hilton; Natalia Ristic; M Caroline Schmid; Lu Zhou; C Oliver Hanemann
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Glia 2012;60(11):1721-33.
2012: Lu Zhou; C Oliver Hanemann
Merlin, a multi-suppressor from cell membrane to the nucleus.
FEBS letters 2012;586(10):1403-8.
2012: Ifat Sher; C Oliver Hanemann; P Andrew Karplus; Anthony Bretscher
The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state.
Developmental cell 2012;22(4):703-5.
2012: Sylwia Ammoun; Emanuela Ercolano; David A Hilton; C M Perks; N Ristic; M C Schmid; L Zhou; C Oliver Hanemann
Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.
Oncogene 2012;31(13):1710-22.
2012: Jaishri Blakeley; Derald Brackmann; Ruihong Chen; D Gareth Evans; Rosalie E Ferner; John Adler; C Oliver Hanemann; Gordon Harris; Kim Hunter-Schaedle; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; BRIGITTE WIDEMANN; Marco Giovannini
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
American journal of medical genetics. Part A 2012;158A(1):24-41.
2011: Lu Zhou; M Caroline Schmid; Sylwia Ammoun; Magdalena A Barczyk; Emanuela Ercolano; C Oliver Hanemann
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Neoplasia (New York, N.Y.) 2011;13(12):1101-12.
2011: Hua Zhang; C Oliver Hanemann; David A Hilton; John Zajicek
Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis.
Brain pathology (Zurich, Switzerland) 2011;21(5):544-57.
2011: Jonathan Cooper; Hediye Erdjument-Bromage; Marco Giovannini; C Oliver Hanemann; Ryohei Ishii; Wei Li; Stephen Barstow Long; Angela Pepe-Caprio; Gaia Schiavon; Paul Tempst; Liru You; Lu Zhou; Pengbo Zhou; Filippo G Giancotti
Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.
Science signaling 2011;4(188):pt6.
2011: Sylwia Ammoun; Paul Manley; Marei Caroline Schmid; Joceline Triner; C Oliver Hanemann
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Neuro-oncology 2011;13(7):759-66.
2011: Sylwia Ammoun; C Oliver Hanemann
Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
Nature reviews. Neurology 2011;7(7):392-9.
2010: Camille Carroll; Konrad Krolikowski; William Mukonoweshuro; Jonathan Jones; C Oliver Hanemann
Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon.
Journal of neurology 2010;257(12):2094-6.
2010: Sylwia Ammoun; Clare H Cunliffe; Jeffrey C Allen; Luis Chiriboga; Filippo G Giancotti; David Zagzag; C Oliver Hanemann; Matthias A Karajannis
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Neuro-oncology 2010;12(8):834-43.
2010: Ibrahim Imam; Susan Ball; Dave Wright; C Oliver Hanemann; John Zajicek
The epidemiology of motor neurone disease in two counties in the southwest of England.
Journal of neurology 2010;257(6):977-81.
2010: Wei Li; Liru You; Jonathan Cooper; Gaia Schiavon; Angela Pepe-Caprio; Lu Zhou; Ryohei Ishii; Marco Giovannini; C Oliver Hanemann; Stephen Barstow Long; Hediye Erdjument-Bromage; Pengbo Zhou; Paul Tempst; Filippo G Giancotti
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Cell 2010;140(4):477-90.
2010: Sylwia Ammoun; Natalia Ristic; Cordula Matthies; David A Hilton; C Oliver Hanemann
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.
Neurobiology of disease 2010;37(1):141-6.
2009: Christine Flaiz; Jonathan Chernoff; Sylwia Ammoun; Jeffrey Peterson; C Oliver Hanemann
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.
Experimental neurology 2009;218(1):137-44.
2009: Ibrahim Imam; Simon Edwards; C Oliver Hanemann
Acquired neuromyotonia following upper respiratory tract infection: a case report.
Cases journal 2009;2():7952.
2008: Sylwia Ammoun; Christine Flaiz; Natalia Ristic; Jennifer Schuldt; C Oliver Hanemann
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Cancer research 2008;68(13):5236-45.
2008: C Flaiz; Tamara Utermark; D B Parkinson; A Poetsch; C Oliver Hanemann
Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.
Glia 2008;56(5):506-15.
2007: C Oliver Hanemann; Ruth Diebold; Dieter Kaufmann
Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.
Brain pathology (Zurich, Switzerland) 2007;17(4):371-6.
2007: Christine Flaiz; Katherine Kaempchen; Cordula Matthies; C Oliver Hanemann
Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas.
Journal of neuropathology and experimental neurology 2007;66(7):608-16.
2007: Hans-Jürgen Gdynia; Anne-Dorte Sperfeld; C Oliver Hanemann
[Central core myopathy: a juvenile and adult disease].
Der Nervenarzt 2007;78(4):387-92.
2006: C Oliver Hanemann; D G Evans
News on the genetics, epidemiology, medical care and translational research of Schwannomas.
Journal of neurology 2006;253(12):1533-41.
2006: C Oliver Hanemann; B Bartelt-Kirbach; Ruth Diebold; K Kämpchen; Sonja Langmesser; Tamara Utermark
Differential gene expression between human schwannoma and control Schwann cells.
Neuropathology and applied neurobiology 2006;32(6):605-14.
2006: Mikaela Grönholm; Taru Muranen; Garabet G Toby; Tamara Utermark; C Oliver Hanemann; Erica A Golemis; Olli Carpén
A functional association between merlin and HEI10, a cell cycle regulator.
Oncogene 2006;25(32):4389-98.
2005: C Oliver Hanemann; Albert C Ludolph
Motor protein diseases of the nervous system.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2005;6(4):197-201.
2005: Christoph Münch; Angela Rosenbohm; Anne-Dorte Sperfeld; Ingo Uttner; Sven Reske; Bernd J Krause; Reinhard Sedlmeier; Thomas Meyer; C Oliver Hanemann; Gabriele Stumm; Albert C Ludolph
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD.
Annals of neurology 2005;58(5):777-80.
2005: Tamara Utermark; Simone J A Schubert; C Oliver Hanemann
Rearrangements of the intermediate filament GFAP in primary human schwannoma cells.
Neurobiology of disease 2005;19(1-2):1-9.
2005: Yumiko Hirokawa; Hidenori Nakajima; C Oliver Hanemann; Andreas Kurtz; Silke Frahm; Victor Mautner; Hiroshi Maruta
Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.
Cancer biology & therapy 2005;4(4):379-81.
2005: C Oliver Hanemann; Katherine Kaempchen; Dieter Kaufmann; Bernd J Krause
Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2.
Archives of neurology 2005;62(4):674-5.
2005: Anne-Dorte Sperfeld; C Oliver Hanemann; Albert C Ludolph; Jan Kassubek
Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy.
Neurology 2005;64(4):753-4.
2005: Ruth Diebold; Britta Bartelt-Kirbach; D Gareth Evans; Dieter Kaufmann; C Oliver Hanemann
Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction.
The Journal of molecular diagnostics : JMD 2005;7(1):97-104.
2005: Anne-Dorte Sperfeld; Volker Bretschneider; Leonie Flaith; Alexander Unrath; C Oliver Hanemann; Albert C Ludolph; Jan Kassubek
MR-pathologic comparison of the upper spinal cord in different motor neuron diseases.
European neurology 2005;53(2):74-7.
2005: Tamara Utermark; Katherine Kaempchen; Gregor Antoniadis; C Oliver Hanemann
Reduced apoptosis rates in human schwannomas.
Brain pathology (Zurich, Switzerland) 2005;15(1):17-22.
2004: Anne-Dorte Sperfeld; Jan Kassubek; Andrew H Crosby; Beate Winner; Albert C Ludolph; Ingo Uttner; C Oliver Hanemann
Complicated hereditary spastic paraplegia with thin corpus callosum: variation of phenotypic expression over time.
Journal of neurology 2004;251(10):1285-7.
2004: Christoph Münch; Reinhard Sedlmeier; Thomas Meyer; V Homberg; Anne-Dorte Sperfeld; A Kurt; Johannes Prudlo; G Peraus; C Oliver Hanemann; Gabriele Stumm; Albert C Ludolph
Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS.
Neurology 2004;63(4):724-6.
2004: Maggie C Walter; J A Petersen; Rolf Stucka; Dirk Fischer; Rolf Schröder; Matthias Vorgerd; Anja Schroers; Herbert Schreiber; C Oliver Hanemann; Ursula I Knirsch; Angela Rosenbohm; Angela Huebner; Nina Barisic; Rita Horvath; Sámuel Komoly; Peter Reilich; Wolfgang Müller-Felber; Dieter Pongratz; Juliane S Müller; Ennes A Auerswald; Hanns Lochmüller
FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients.
Journal of medical genetics 2004;41(4):e50.
2004: Yumiko Hirokawa; Anjali Tikoo; John Huynh; Tamara Utermark; C Oliver Hanemann; Marco Giovannini; Guang-Hui Xiao; Joseph R Testa; John Wood; Hiroshi Maruta
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Cancer journal (Sudbury, Mass.) 2004;10(1):20-6.
2003: Tamara Utermark; Katherine Kaempchen; C Oliver Hanemann
Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins.
Brain pathology (Zurich, Switzerland) 2003;13(3):352-63.
2003: C Oliver Hanemann; Albert C Ludolph
ALS/MND meeting of the European AlS/MND group Reisensburg Castle 30 January - 1 February 2003.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2003;4(2):121-2.
2003: Katherine Kaempchen; Kirsten Mielke; Tamara Utermark; Sonja Langmesser; C Oliver Hanemann
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.
Human molecular genetics 2003;12(11):1211-21.
2003: Tamara Utermark; Alexi K. Alekov; Holger Lerche; Vincent Abramowski; Marco Giovannini; C Oliver Hanemann
Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells.
Cancer 2003;97(8):1955-62.
2003: C Oliver Hanemann; Carsten Bergmann; Jan Senderek; Klaus Zerres; Anne-Dorte Sperfeld
Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation.
Archives of neurology 2003;60(4):605-9.
2003: Stephan Zuchner; Anne-Dorte Sperfeld; Jan Senderek; Bernd Sellhaus; C Oliver Hanemann; J Michael Schröder
A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease.
Brain : a journal of neurology 2003;126(Pt 4):920-7.
2003: Abdelwahed Chtarto; H U Bender; C Oliver Hanemann; T Kemp; E Lehtonen; Marc Levivier; Jacques Brotchi; Thierry Velu; Liliane Tenenbaum
Tetracycline-inducible transgene expression mediated by a single AAV vector.
Gene therapy 2003;10(1):84-94.
2002: C Oliver Hanemann; Albert C Ludolph
Hereditary motor neuropathies and motor neuron diseases: which is which.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2002;3(4):186-9.
2002: Anne-Dorte Sperfeld; Jochen Karitzky; Dagmar Brummer; Herbert Schreiber; Jürgen Häussler; Albert C Ludolph; C Oliver Hanemann
X-linked bulbospinal neuronopathy: Kennedy disease.
Archives of neurology 2002;59(12):1921-6.
2002: C Oliver Hanemann; Anneke A W M Gabreels-Festen
Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies.
Current opinion in neurology 2002;15(5):611-5.
2002: Anne-Dorte Sperfeld; Christian Hein; J M Schröder; A C Ludolph; C Oliver Hanemann
Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.
Brain : a journal of neurology 2002;125(Pt 5):996-1004.
2002: K M M Schulze; C Oliver Hanemann; Hans Werner Müller; Helmut Hanenberg
Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
Human molecular genetics 2002;11(1):69-76.
2001: Dieter Kaufmann; Ralf Müller; Britta Bartelt; Michael Wolf; Karin Kunzi-Rapp; C Oliver Hanemann; R Fahsold; Christian Hein; Walther Vogel; Günter Assum
Spinal neurofibromatosis without café-au-lait macules in two families with null mutations of the NF1 gene.
American journal of human genetics 2001;69(6):1395-400.
2001: C Oliver Hanemann; A A W M Gabreëls-Festen; Peter De Jonghe
Axon damage in CMT due to mutation in myelin protein P0.
Neuromuscular disorders : NMD 2001;11(8):753-6.
2001: C Oliver Hanemann
Hereditary demyelinating neuropathies: from gene to disease.
Neurogenetics 2001;3(2):53-7.
2000: Thorsten Rosenbaum; Claudia Rosenbaum; U Winner; Hans Werner Müller; Hans-Gerd Lenard; C Oliver Hanemann
Long-term culture and characterization of human neurofibroma-derived Schwann cells.
Journal of neuroscience research 2000;61(5):524-32.
2000: Claudia Rosenbaum; Martin Kamleiter; Peter Grafe; Lan Kluwe; Victor Mautner; Hans Werner Müller; C Oliver Hanemann
Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine.
Neurobiology of disease 2000;7(4):483-91.
2000: C Oliver Hanemann; D D'Urso; A A W M Gabreëls-Festen; Hans Werner Müller
Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A.
Brain : a journal of neurology 2000;123 ( Pt 5)():1001-6.
1999: Liliane Tenenbaum; Malika Hamdane; M Pouzet; B Avalosse; A Stathopoulos; F Jurysta; Claudia Rosenbaum; C Oliver Hanemann; Marc Levivier; Thierry Velu
Cellular contaminants of adeno-associated virus vector stocks can enhance transduction.
Gene therapy 1999;6(6):1045-53.
1999: C Mayer; Martin Kamleiter; R Sanchez-Brandelik; Claudia Rosenbaum; Lan Kluwe; C Oliver Hanemann; Peter Grafe
Neuroligand-mediated calcium signaling in cultured human schwannoma cells.
Journal of the peripheral nervous system : JPNS 1999;4(2):99-105.
1998: Martin Kamleiter; C Oliver Hanemann; Lan Kluwe; Claudia Rosenbaum; S Wosch; V F Mautner; Hans Werner Müller; Peter Grafe
Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells.
Glia 1998;24(3):313-22.
1998: Guido Stoll; A A W M Gabreëls-Festen; Sebastian Jander; Hans Werner Müller; C Oliver Hanemann
Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies.
Muscle & nerve 1998;21(11):1419-27.
1998: Claudia Rosenbaum; Lan Kluwe; V F Mautner; R E Friedrich; Hans Werner Müller; C Oliver Hanemann
Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients.
Neurobiology of disease 1998;5(1):55-64.
1998: C Oliver Hanemann; Hans Werner Müller
Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
Trends in neurosciences 1998;21(7):282-6.
1998: C Oliver Hanemann; Claudia Rosenbaum; S Kupfer; S Wosch; F Stoegbauer; Hans Werner Müller
Improved culture methods to expand Schwann cells with altered growth behaviour from CMT1A patients.
Glia 1998;23(2):89-98.
1997: Susanne Hermanns; G Wunderlich; Claudia Rosenbaum; C Oliver Hanemann; Hans Werner Müller; CC Stichel
Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions.
Glia 1997;21(3):299-314.
1997: C Oliver Hanemann; A A W M Gabreëls-Festen; Guido Stoll; Hans Werner Müller
Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Acta neuropathologica 1997;94(4):310-5.
1997: Hans Werner Müller; U Suter; Christine Van Broeckhoven; C Oliver Hanemann; Eva Nelis; Vincent Timmerman; S Sancho; L Barrio; P Bolhuis; R Dermietzel; M Frank; A A W M Gabreëls-Festen; C Gillen; N Haites; G Levi; Edwin C M Mariman; R Martini; K Nave; Bernd Rautenstrauss; M Schachner; A Schenone; C Schneider; M Schröder; Klaus Willecke; O Haneman
Advances in Charcot-Marie-Tooth disease research: cellular function of CMT-related proteins, transgenic animal models, and pathomechanisms. The European CMT Consortium.
Neurobiology of disease 1997;4(3-4):215-20.
1996: C Oliver Hanemann; A A Gabreëls-Fasten; Hans Werner Müller; Guido Stoll
Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages.
Brain : a journal of neurology 1996;119 ( Pt 5)():1461-9.
1996: C Oliver Hanemann; H Hefter; G Schlaug; Rüdiger J Seitz; Hans-Joachim Freund; R Benecke
Characterization of basal ganglia dysfunction in Leber 'plus' disease.
Journal of neurology 1996;243(3):297-300.
1995: C Oliver Hanemann; Guido Stoll; Hans Werner Müller
PMP22 expression in CMT1a neuropathy.
Annals of neurology 1995;37(1):136.
1994: C Oliver Hanemann; Guido Stoll; D D'Urso; W Fricke; J J Martin; Christine Van Broeckhoven; G L Mancardi; I Bartke; Hans Werner Müller
Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Journal of neuroscience research 1994;37(5):654-9.
1993: C Oliver Hanemann; G Kuhn; A Lie; C Gillen; Frank Bosse; P Spreyer; Hans Werner Müller
Expression of decorin mRNA in the nervous system of rat.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1993;41(9):1383-91.
1993: C Oliver Hanemann; A Kleinschmidt; G Reifenberger; Hans-Joachim Freund; Rüdiger J Seitz
Balo's concentric sclerosis followed by MRI and positron emission tomography.
Neuroradiology 1993;35(8):578-80.
1992: Vincent Timmerman; Eva Nelis; Wim Van Hul; B W Nieuwenhuijsen; KL Chen; S Wang; K Ben Othman; B Cullen; Robin J Leach; C Oliver Hanemann
The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication.
Nature genetics 1992;1(3):171-5.
1991: P Spreyer; G Kuhn; C Oliver Hanemann; C Gillen; Heiner Schaal; R Kuhn; G Lemke; Hans Werner Müller
Axon-regulated expression of a Schwann cell transcript that is homologous to a 'growth arrest-specific' gene.
The EMBO journal 1991;10(12):3661-8.